Tharimmune (NASDAQ:THAR) Stock Price Down 3.5% – Time to Sell?

Tharimmune, Inc. (NASDAQ:THAR) shares dropped 3.5% during trading on Monday . The company traded as low as $3.50 and last traded at $3.62. Approximately 431,328 shares were traded during trading, a decline of 71% from the average daily volume of 1,476,877 shares. The stock had previously closed at $3.75.

Tharimmune Price Performance

The stock has a market capitalization of $123.19 million, a P/E ratio of -0.82 and a beta of 1.43. The company’s 50 day simple moving average is $3.46 and its two-hundred day simple moving average is $3.44.

Institutional Trading of Tharimmune

A number of institutional investors have recently bought and sold shares of the business. ARK Investment Management LLC acquired a new position in shares of Tharimmune in the 4th quarter valued at $9,854,000. Clear Street Group Inc. bought a new stake in Tharimmune in the fourth quarter valued at about $5,066,000. Feynman Point Asset Management LLC acquired a new position in Tharimmune in the fourth quarter valued at about $1,314,000. Marshall Wace LLP bought a new stake in shares of Tharimmune in the 4th quarter valued at about $1,030,000. Finally, Geode Capital Management LLC boosted its stake in Tharimmune by 1,102.6% during the 4th quarter. Geode Capital Management LLC now owns 335,923 shares of the company’s stock worth $1,018,000 after acquiring an additional 307,991 shares during the last quarter. Institutional investors and hedge funds own 1.16% of the company’s stock.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc for the development of proprietary targeted biologics; and Washington University in St.